ClinicalTrials.gg
CompletedNCT04507659ASUpdated Mar 29, 2023

Jaktinib Hydrochloride Tablets In The Treatment of Active Ankylosing Spondylitis

A Phase 2 interventional study of Jaktinib Hydrochloride Tablets and Jaktinib Hydrochloride Tablets in Ankylosing Spondylitis, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-03-29.

Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 76 studies in Spondylitis, Ankylosing with a site in China — 19 open to participants now, 22 under way, 4 of them phase 3. Spondylitis, Ankylosing · China.

Enrollment
39th of 62
108 · median 150
Started
2020
with 4 others
Phase 2
11 of 76
none open now
Registered
37th of 76
by date
Lead sponsor
3 of 76
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Among the 76 studies in Spondylitis, Ankylosing with a site in China, this one is the 39th largest by enrollment of the 62 interventional ones that give a count, is one of 5 that started in 2020, is one of 11 in phase 2, and was the 37th registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

19 of the 76 studies in Spondylitis, Ankylosing with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Spondylitis, Ankylosing with a site in China, or all of them as a file.
02

Study summary

This trial uses a multi-center, randomized, double-blind, placebo, parallel-controlled design, and it is expected that about 105 cases will be enrolled in about 10 sites.

Read the detailed description

The study is divided into two stages, the first stage (1-16 weeks) is the main study; the second stage (17-32 weeks) is the extended study. This study set up 3 groups:Jaktinib Hydrochloride Tablets 75mg Bid group, 100mg Bid group and a placebo control group. The subjects were randomly enrolled in the group 1:1:1.

03

Conditions studied

  • Ankylosing Spondylitis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-65, both gender;
  • Active Ankylosing Spondylitis;
  • Participants who have been treated with non-steroidal anti-inflammatory drugs(NSAIDs) and still have active disease, or Participants who are intolerant to NSAIDs and stop the drug;
  • Participants receiving low-dose oral therapy (≤10mg/d prednisone) should maintain a stable medication regimen for at least 4 weeks before the first dose of this study. Do not adjust the dose during the entire study period except in emergency situations.
  • Participants receiving other non-prohibited co-drugs should maintain a stable medication regimen for at least 7 days before the first dose of this study;
  • Understand and voluntarily signed .

Exclusion criteria

Exclusion Criteria:

  • A history of known or suspected complete spinal rigidity, or clinical and imaging confirmed complete spinal rigidity;
  • A history of any other rheumatic disease;
  • Any history of joint prosthesis infection, and the prosthesis is still in place;
  • Participants who are using strong opioid analgesics (such as methadone, hydromorphone, morphine, etc.);
  • Participants who have been treated with any JAK inhibitors (such as Tofacitinib, Baricitinib, Ruxolitinib, Filgotinib, Upadacitinib, etc.);
  • Participants who have drug abuse or alcohol dependence;
  • Participants who have had herpes virus infection in the past month;
  • Participants who have a history of venous thrombosis (regardless of current treatment);
  • Any significant clinical and laboratory abnormalities that the investigator believes will affect the safety evaluator;
  • Participants who cannot be treated and followed up according to the trial protocol;
  • Any Participant considered by the investigator to be unsuitable to participate in this clinical study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    Jaktinib 100mg

    100 mg bid.po

    Drug: Jaktinib Hydrochloride Tablets

  • Experimental
    Jaktinib 75mg

    75 mg bid.po

    Drug: Jaktinib Hydrochloride Tablets

  • Placebo comparator
    Placebo

    Placebo bid.po

    Drug: Placebo

Interventions

  • Morning: 2\*50mg simulated tablets and 1\*75mg Jaktinib Hydrochloride Tablets; Evening: 2\*50mg simulated tablets and 1\*75mg Jaktinib Hydrochloride Tablets.

    Also known as: Jaktinib

  • Morning: 1\*75mg simulated tablet, 2\*50mg Jaktinib Hydrochloride Tablets; Evening: 1\*75mg simulated tablet, 2\*50mg Jaktinib Hydrochloride Tablets.

    Also known as: Jaktinib

  • DrugPlacebo

    Morning: 1\*75mg simulated tablet, 2\*50mg simulated tablets; Evening: 1\*75mg simulated tablet, 2\*50mg simulated tablets.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving 20 Percent (%) Improvement in Assessment of SpondyloArthritis International Society (ASAS) Score (ASAS 20) at Week 16

    ASAS20 responder had improvement of greater than or equal to (≥) 20% and ≥1 unit in at least 3 domains (on a scale of 0 \[least\] to 10 \[worst\]) and no worsening of ≥20% and less than or equal to (≤)1 unit in the remaining domain. The domains are: Patient's Global Assessment of Disease Activity, spinal pain, function and inflammation (from Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Missing data were handled by nonresponsive (NRI)/ last observation carried forward (LOCF). Missing values due to a subject dropping out from the study were handled by setting the ASAS20 value to NRI. The LOCF approach was applied to missing components, if just some of the components of the ASAS20 were missing.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Achieving ASAS 20 at Week 2, 4, 8, 12, 20, 24, and 32

    It assess the disease activity. It was evaluated with a 6-question questionnaire. After taking the answer of each question out of 10, the total of the points was calculated by dividing the number of questions.The score range was 0-10, the low score meant that the spinal movement was better.

    Time frame: Week 2,4,8,12,16,20,24,32

  2. Percentage of Participants Achieving ASAS 40 at Week 2, 4, 8, 12, 16, 20, 24, and 32

    ASAS 40 is defined as ≥40% and absolute change of ≥2 units in at least 3 domains on a 0-10 scale (0=no disease activity, 10=high disease activity), and no worsening in the remaining domain. Missing data were handled by NRI/LOCF.

    Time frame: Week 2,4,8,12,16,20,24,32

  3. Percentage of Participants Achieving ASAS 70 at Week 2, 4, 8, 12, 16, 20, 24, and 32

    It characterises the spinal mobility of patients with ankylosing spondylitis. Cervical rotation, tragus-wall distance, lateral lumbar flexion, anterior lumbar flexion (modified schober), intermalleolar distance were measured. The score range was 0-10, the low score meant that the spinal movement was better.

    Time frame: Week 2,4,8,12,16,20,24,32

  4. Percentage of Participants Achieving ASAS 5/6 Response at Weeks 2, 4, 8, 12, 16, 20, 24, and 32

    ASAS5/6 consists of 6 domains: the 4 used in ASAS20 (Patient's Global Assessment of Disease Activity, spinal pain, function, inflammation plus spinal mobility and an acute phase reactant, C Reactive Protein (CRP). ASAS 5/6 is defined as ≥20% improvement in at least 5 domains and no worsening in the remaining domain. Missing data were handled by NRI/LOCF.

    Time frame: Week 2,4,8,12,16,20,24,32

07

Study locations

1 site
  • Renji Hospital
    Shanghai, Shanghai 200011, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Aug 2022, 20 months.

Of 22 phase 2 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 20 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2020
First posted
Aug 11, 2020
StartActual
Dec 1, 2020
Primary completionActual
Aug 2, 2022
CompletionActual
Aug 2, 2022
Last update
Mar 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04507659
Responsible party
Sponsor
First posted
Aug 11, 2020
Start date
Dec 1, 2020
Primary completion
Aug 2, 2022
Completion
Aug 2, 2022
Last update
Mar 29, 2023

Study contacts

Chunde Bao, MD
principal investigator · RenJi Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Jaktinib

Start the discussion